How Incarceration Raises Risk of Cancer Diagnosis and Death—Even After Release
The United States has one of the highest incarceration rates in the world, with nearly 2 million people in the criminal justice system facing potential barriers to accessing timely, quality care. Now, Yale researchers are finding that individuals with a history of incarceration are more likely to be diagnosed with cancer and are less likely to survive the disease.
Multidisciplinary COPPER Center Brings a Public Health Lens to Cancer Care
Studying cancer treatment outcomes is the mission of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, a collaborative effort of the Yale Cancer Center and the Schools of Medicine and Public Health.Source: Yale Public Health magazine
Smilow Cancer Hospital and Yale Police Team to Raise Breast Cancer Awareness
Members of Smilow Cancer Hospital and Yale Cancer Center spent time together on Friday, October 28 on the New Haven Green with members of the Yale Police Department – along with a special, pink-themed Yale Police SUV – to highlight Breast Cancer Awareness Month.
Scientists researching new scientific approach to identify cancer origins
Previous studies have shown the connection between age, exposure to carcinogens and the risk of developing cancer due to the accumulation of mutations over time. Scientists from Yale University and Emmanuel College demonstrate a new scientific approach to determine the origins of different types of cancer. Jeffrey Townsend, YSPH Elihu Professor of Biostatistics and Ecology & Evolutionary Biology, was a co-author of the study.Source: The Daily Campus
Children who live near fracking sites at birth face increased risk of leukemia: study
Pennsylvania children living near fracking sites at birth are two to three times more likely to be diagnosed with leukemia during early childhood than those who did not live near such facilities, a new study has found.Source: The Hill
Yale Study Identifies Causes of Cancers
A team of Yale-led researchers can now quantify the factors causing changes in the DNA that contribute most to cancer growth in tumors of most major tumor types. Their molecular analysis approach brings clarity to a longstanding debate over how much control humans have over developing cancer over time.
How to Tell whether a Cancer Is Caused by Plain Bad Luck
Cancer results from a combination of spontaneous mutations that arise with age—just call it “bad luck”—and environmental exposures to carcinogens such as tobacco, ultraviolet light or viruses. But the question of the relative contribution of luck—compared with more explicit causes—has generated vigorous debate for years.Source: Scientific American
Irwin receives $7 million grant to investigate healthy interventions for ovarian cancer patients
Yale School of Public Health Associate Dean of Research and Susan Dwight Bliss Professor of Epidemiology Melinda Irwin, Ph.D., M.P.H., has been awarded a five-year, $7 million grant from the National Cancer Institute to explore how nutrition and exercise interventions can improve chemotherapy outcomes and reduce toxicity for women with ovarian cancer.
Yale-led Study Finds the Affordable Care Act Prevented Thousands of Colorectal Cancer Cases and Deaths
Can removing out-of-pocket costs for screening save lives? Screening for cancer and other diseases can identify the disease in its earlier stages of development and has been found to be highly effective in preventing the onset of illness.
It's Time to Trade the Moonshot Mentality for a New National Cancer Plan
The fixation on finding a cure for cancer — a moonshot — is diverting our attention, energy and resources from the broader picture. At the 50th anniversary of the National Cancer Act, people are still getting cancers that should be preventable. And profound inequities in cancer burden persist across racial and ethnic groups and social classes. We need a new National Cancer Plan.Source: The Hill
Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients With Advanced Lung Cancer
New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer.